查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496118

集落刺激因子（CSF）治療市場：現況分析與預測（2024-2032）

Colony-Stimulating Factor Therapy Market: Current Analysis and Forecast (2024-2032)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 134 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

由於肢體缺陷盛行率不斷增加，集落刺激因子 (CSF) 治療市場預計在預測期內將以 10.6% 的複合年增長率強勁增長。集落刺激因子 (CSF) 治療市場是指專注於開發、生產和銷售被稱為集落刺激因子的藥品的製藥業部分。這些藥物用於刺激免疫系統因癌症、化療、骨髓移植或某些感染而減弱的患者產生白血球（特別是粒細胞、巨噬細胞和血小板）。隨著全球癌症發生率持續上升，對集落刺激因子的需求也在增加，集落刺激因子通常用作癌症治療中的支持療法，以控制化療引起的中性粒細胞減少症。例如，根據泛美衛生組織估計，到2023年，全球將新增2,000萬癌症病例，1,000萬人死於癌症。未來 20 年，癌症負擔預計將增加約 60%，進一步加重衛生系統、人民和社區的負擔。

依類型，市場包括巨噬細胞集落刺激因子（M-CSF）、多集落刺激因子或白血球介素3（IL-3）、粒細胞巨噬細胞集落刺激因子（GM-CSF），它被分類為球狀-集落刺激因子（G-CSF）。其中，粒細胞集落刺激因子（G-CSF）細分市場預計將以較高的複合年增長率成長。 G-CSF 通常用作化療期間的支持療法，以降低發燒性嗜中性白血球減少症的風險，這是一種以白血球計數低和發燒為特徵的嚴重併發症。隨著化療使用的擴大，對 G-CSF 的需求也在增加，以減少其相關的副作用。此外，G-CSF製劑的不斷進步促使了長效製劑的開發，這種製劑需要更少的劑量，增加了患者的便利性和對治療方案的依從性。

市場依藥物分為聚乙二醇非格司亭、TBO非格司亭、沙格司亭、非格司亭等。其中，非格司亭細分市場預計將以較高的複合年增長率成長。非格司亭在刺激接受化療或骨髓移植的患者產生嗜中性球（一種白血球）方面顯示出功效，可降低發燒性嗜中性白血球減少症及其相關併發症的風險。此外，非格司亭已被證明可有效治療化療引起的中性粒細胞減少症，包括動員外周血祖細胞進行移植、治療嚴重的慢性中性粒細胞減少症以及預防艾滋病毒感染患者的中性粒細胞減少症，它也在各種臨床情況中得到了應用。

依用途分為再生障礙性貧血、骨髓移植、嗜中性白血球減少症、化療引起的嗜中性白血球減少症、放射線引起的中性白血球減少症、週邊祖細胞移植等。化療相關的中性粒細胞減少症預計在未來一段時間內將以高複合年增長率增長。隨著全球癌症發生率的上升，越來越多的患者正在接受化療，這通常會導致中性粒細胞減少症。化療藥物會抑制骨髓產生白血球（包括嗜中性球）的能力，使患者更容易受到感染。此外，化療不僅越來越多地被用作癌症的主要治療，而且還被用作與手術或放射治療相結合的輔助或新輔助治療。此類化療的廣泛應用導致中性粒細胞減少症風險族群的增加。

依最終用戶劃分，市場分為醫院、專科診所、家庭醫療保健等。 2023年的市場中，醫院領域將佔據壓倒性佔有率。醫院是癌症、自體免疫疾病和嚴重感染等嚴重疾病患者的初級護理機構，這些患者通常需要使用集落刺激因子 (CSF) 療法作為支持性護理。隨著這些疾病的全球發生率不斷增加，醫院環境中對集落刺激因子的需求也增加。

根據銷售管道，市場分為醫院藥局、零售藥局和網路藥局。醫院藥房預計將在一段時間內以較高的複合年增長率增長。醫院藥房充當醫院內配藥的中心中心。醫院藥房備有多種藥物，包括促定植劑，並為接受醫院護理的患者及時提供這些藥物。此外，醫院藥房配備了經過專門培訓和專業知識的藥劑師和藥劑師技術人員，可以管理複雜的藥物治療方案，包括集落刺激因子等支持性治療。

為了更瞭解集落刺激因子（CSF）治療產業的市場實施情況，將市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利） ，歐洲其他地區），根據亞太地區（中國、日本、印度、亞太地區其他地區）、世界其他地區的全球影響力進行分析。北美在市場上佔據主導地位，預計這一趨勢在預測期內將持續下去。北美集落刺激因子（CSF）治療市場由多種因素驅動。與其他地區相比，北美的癌症發生率相對較高，導致大量患者需要化療和支持性治療，包括集落刺激因子。癌症流行正在推動該地區對集落刺激因子 (CSF) 治療的需求。此外，北美人口正在老化，癌症和其他需要化療和支持性護理的與年齡相關的疾病的盛行率不斷增加。隨著人口老化，對集落刺激因子的需求不斷增加，以控制治療相關的副作用並改善患者的治療效果。

目錄

第一章市場介紹

  • 市場定義
  • 主要目標
  • 利害關係人
  • 限制

第二章研究方法或前提

  • 調查過程
  • 調查方法
  • 受訪者簡介

第三章市場總結

第 4 章執行摘要

第 5 章 COVID-19 對集落刺激因子 (CSF) 治療市場的影響

第 6 章全球集落刺激因子 (CSF) 治療市場收入，2022-2032 年

第 7 章市場分析：依類型

  • 巨噬細胞集落刺激因子 (M-CSF)
  • 多集落刺激因子，或白血球介素 3 (IL-3)
  • 粒細胞巨噬細胞集落刺激因子 (GM-CSF)
  • 粒細胞集落刺激因子 (G-CSF)

第 8 章市場分析：依藥物

  • 培非格司亭
  • Tbo非格司亭
  • 沙格司汀
  • 非格司亭
  • 其他

第 9 章市場分析：依應用

  • 再生不良性貧血
  • 骨髓移植
  • 嗜中性白血球減少症
  • 化療相關的中性白血球減少症
  • 輻射相關的中性白血球減少症
  • 週邊血幹細胞移植

第 10 章市場分析：依最終使用者劃分

  • 醫院
  • 專科診所
  • 家庭醫療護理
  • 其他

第 11 章市場分析：依通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 12 章市場分析：依地區

  • 北美集落刺激因子 (CSF) 治療市場
    • 美國
    • 加拿大
    • 其他北美地區
  • 歐洲集落刺激因子 (CSF) 治療市場
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲地區
  • 亞太地區集落刺激因子 (CSF) 治療市場
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 其他地區的集落刺激因子（CSF）治療市場

第 13 章集落刺激因子 (CSF) 治療市場動態

  • 市場驅動因素
  • 市場課題
  • 影響分析

第 14 章集落刺激因子 (CSF) 治療市場機會

第 15 章集落刺激因子 (CSF) 治療市場趨勢與見解

第十六章需求方與供給方分析

  • 需求方分析
  • 供給面分析

第十七章價值鏈分析

第十八章價格分析

第十九章競爭場景

  • 競爭狀況
    • 波特五力分析

第20章公司簡介

  • Sanofi
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Amgen Inc.
  • Merck KGaA
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc

第 21 章免責聲明

簡介目錄
Product Code: UMHE212756

The Colony-stimulating factor therapy Market is expected to grow at a strong CAGR of 10.6% during the forecast period owing to increasing prevalence of limb loss. The colony stimulating factor (CSF) therapy market refers to the segment of the pharmaceutical industry focused on the development, production, and sale of medications known as colony stimulating factors. These medications are used to stimulate the production of white blood cells (specifically granulocytes, macrophages, and platelets) in patients whose immune systems are compromised due to conditions such as cancer, chemotherapy, bone marrow transplant, or certain infections. As the incidence of cancer continues to rise globally, the demand for colony stimulating factors, which are often used as supportive care in cancer treatment to manage chemotherapy-induced neutropenia, is also increasing. For instance, according to PAHO, in 2023, Globally, there were an estimated 20 million new cases of cancer and 10 million deaths from cancer. The cancer burden will increase by approximately 60% over the next two decades, further straining health systems, people and communities.

Based on the Type, the market has been categorized into macrophage-colony-stimulating factor (M-CSF), multiple-colony-stimulating factor, or interleukin 3 (IL-3), granulocyte-macrophage-colony-stimulating factor (GM-CSF), granulocyte-colony-stimulating factor (G-CSF). Among them, the granulocyte-colony-stimulating factor (G-CSF) segment is expected to grow at a higher CAGR in the market. G-CSFs are commonly used as supportive therapy during chemotherapy to reduce the risk of febrile neutropenia, a potentially serious complication characterized by a low white blood cell count and fever. As the use of chemotherapy expands, so does the demand for G-CSF to mitigate associated side effects. Moreover, Continuous advancements in G-CSF formulations have led to the development of long-acting versions that require less frequent administration, improving patient convenience and adherence to treatment regimens

Based on the drug, the market has been categorized into pegfilgrastim, tbo-filgrastim, sargramostim, filgrastim, others. Among them, the filgrastim segment is expected to grow at a higher CAGR in the market. Filgrastim has a well-established track record of efficacy in stimulating the production of neutrophils (a type of white blood cell) in patients undergoing chemotherapy or bone marrow transplantation, thereby reducing the risk of febrile neutropenia and its associated complications. Moreover, Filgrastim is indicated for a variety of clinical scenarios beyond chemotherapy-induced neutropenia, including mobilization of peripheral blood progenitor cells for transplantation, treatment of severe chronic neutropenia, and prevention of neutropenia in patients with HIV infection, expanding its market potential.

By application, the market is categorized into aplastic anemia, bone marrow transplantation, neutropenia, neutropenia associated with chemotherapy, neutropenia associated with radiation, peripheral progenitor cell transplantation. The neutropenia associated with chemotherapy is anticipated to grow with high CAGR during the forthcoming period. With the rising incidence of cancer globally, more patients are undergoing chemotherapy, which often leads to neutropenia. Chemotherapy drugs can suppress the bone marrow's ability to produce white blood cells, including neutrophils, leaving patients vulnerable to infections. Moreover, Chemotherapy is being increasingly utilized not only as a primary treatment for cancer but also in adjuvant and neoadjuvant settings, in combination with surgery or radiation therapy. This broader application of chemotherapy contributes to a larger population at risk of developing neutropenia.

Based on end-users, the market is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment held a dominant share of the market in 2023. Hospitals are the primary care facilities for patients with serious illnesses such as cancer, autoimmune diseases, and severe infections, which often necessitate the use of colony stimulating factor therapy as supportive care. With the growing incidence of these conditions globally, there is a corresponding increase in the demand for colony stimulating factors in hospital settings.

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies are anticipated to grow with high CAGR during the forthcoming period. Hospital pharmacies serve as centralized hubs for medication dispensing within the hospital setting. They stock a wide range of pharmaceutical products, including colony stimulating factors, and provide timely access to these medications for patients undergoing treatment in the hospital. Moreover, hospital pharmacies are staffed with pharmacists and pharmacy technicians who have specialized training and expertise in managing complex medication regimens, including supportive therapies like colony stimulating factors.

For a better understanding of the market adoption of the colony-stimulating factor therapy industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America holds the dominant share of the market and is expected to do so even in the forecast period. The North America colony-stimulating factor therapy market is being driven by several factors. North America has a relatively high incidence of cancer compared to other regions, contributing to a large patient population requiring chemotherapy and supportive care, including colony stimulating factors. The prevalence of cancer drives the demand for colony stimulating factor therapy in the region. Moreover, the aging population in North America is driving an increase in the prevalence of cancer and other age-related conditions requiring chemotherapy and supportive therapies. As the population ages, there is a higher demand for colony stimulating factors to manage treatment-related side effects and improve patient outcomes.

Some of the major players operating in the market include Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd., Amgen Inc., Merck KGaA, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Colony-Stimulating Factor Therapy Market
  • 2.2. Research Methodology of the Colony-Stimulating Factor Therapy Market
  • 2.4. Respondent Profile

3.MARKET SYNOPSIS

4.EXECUTIVE SUMMARY

5.IMPACT OF COVID-19 ON THE COLONY-STIMULATING FACTOR THERAPY MARKET

6.GLOBAL COLONY-STIMULATING FACTOR THERAPY MARKET REVENUE, 2022-2032F

7.MARKET INSIGHTS BY TYPE

  • 7.1. Macrophage-Colony-Stimulating Factor (M-CSF)
  • 7.2. Multiple-Colony-Stimulating Factor, or Interleukin 3 (IL-3)
  • 7.3. Granulocyte-Macrophage-Colony-Stimulating Factor (GM-CSF)
  • 7.4. Granulocyte-Colony-Stimulating Factor (G-CSF)

8.MARKET INSIGHTS BY DRUG

  • 8.1. Pegfilgrastim
  • 8.2. Tbo-filgrastim
  • 8.3. Sargramostim
  • 8.4. Filgrastim
  • 8.5. Others

9.MARKET INSIGHTS BY APPLICATION

  • 9.1. Aplastic Anemia
  • 9.2. Bone Marrow Transplantation
  • 9.3. Neutropenia
  • 9.4. Neutropenia Associated with Chemotherapy
  • 9.5. Neutropenia Associated with Radiation
  • 9.6. Peripheral Progenitor Cell Transplantation

10.MARKET INSIGHTS BY END-USERS

  • 10.1. Hospitals
  • 10.2. Specialty Clinics
  • 10.3. Homecare
  • 10.4. Others

11.MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 8.1. Hospital Pharmacies
  • 8.2. Retail Pharmacies
  • 8.3. Online Pharmacies

12.MARKET INSIGHTS BY REGION

  • 12.1 NORTH AMERICA COLONY-STIMULATING FACTOR THERAPY MARKET
    • 12.1.1. U.S.
    • 12.1.2. Canada
    • 12.1.3. Rest of North America
  • 12.2 EUROPE COLONY-STIMULATING FACTOR THERAPY MARKET
    • 12.2.1. Germany
    • 12.2.2. U.K.
    • 12.2.3. France
    • 12.2.4. Italy
    • 12.2.5. Spain
    • 12.2.6. Rest of Europe
  • 12.3 ASIA PACIFIC COLONY-STIMULATING FACTOR THERAPY MARKET
    • 12.3.1. China
    • 12.3.2. Japan
    • 12.3.3. India
    • 12.3.4. Rest of Asia-Pacific
  • 12.4 REST OF THE WORLD COLONY-STIMULATING FACTOR THERAPY MARKET

13.COLONY-STIMULATING FACTOR THERAPY MARKET DYNAMICS

  • 13.1. Market Drivers
  • 13.2. Market Challenges
  • 13.3. Impact Analysis

14.COLONY-STIMULATING FACTOR THERAPY MARKET OPPORTUNITIES

15.COLONY-STIMULATING FACTOR THERAPY MARKET TRENDS & INSIGHTS

16.DEMAND AND SUPPLY SIDE ANALYSIS

  • 16.1. Demand Side Analysis
  • 16.2. Supply Side Analysis

17.VALUE CHAIN ANALYSIS

18.PRICING ANALYSIS

19.COMPETITIVE SCENARIO

  • 19.1. Competitive Landscape
    • 19.1.1 Porter's Five forces analysis

20.COMPANY PROFILED

  • 20.1. Sanofi
  • 20.2. Novartis AG
  • 20.3. Teva Pharmaceutical Industries Ltd.
  • 20.4. Pfizer Inc.
  • 20.5. GlaxoSmithKline plc
  • 20.6. Dr. Reddy's Laboratories Ltd.
  • 20.7. Amgen Inc.
  • 20.8. Merck KGaA
  • 20.9. Takeda Pharmaceutical Company Limited
  • 20.10. Thermo Fisher Scientific Inc

21.DISCLAIMER